Biotech-Pharma Collaboration-A Strategic Tool: Case Study of Centocor

Lara V. Marks*

*Corresponding author for this work

Research output: Chapter in Book/Report/Conference proceedingChapterpeer-review


Collaboration is one of the key strategic tools for pharmaceutical and biotechnology companies, being used to enhance a company's research and development, product portfolio, and marketing channels. Using Centocor, a pioneering American biotechnology company, as a case-study, this chapter highlights how vital alliances can be to both the initiation and survival of start-ups. As it shows, alliances can provide an important channel for securing products for development as well as funding for getting them to market. The near collapse of Centocor when it switched from a policy of collaboration to going it alone in the development of what they thought would be a blockbuster drug is a salutary reminder for entrepreneurs considering what path to take in building a company.

Original languageEnglish
Title of host publicationBiotechnology Entrepreneurship
Subtitle of host publicationStarting, Managing, and Leading Biotech Companies
EditorsCraig Shimasaki
ISBN (Print)9780124047303
Publication statusPublished - May 2014


  • Alliances
  • Collaboration
  • Diagnostics
  • Funding
  • Monoclonal antibodies
  • Networking
  • Therapeutics


Dive into the research topics of 'Biotech-Pharma Collaboration-A Strategic Tool: Case Study of Centocor'. Together they form a unique fingerprint.

Cite this